Medicine and Dentistry
Pancreas Cancer
100%
Colorectal Cancer
54%
Randomized Controlled Trial
54%
Gemcitabine
50%
Oxaliplatin-Induced Peripheral Neuropathy
50%
Irreversible Electroporation
50%
Liver Metastasis
50%
Combination Chemotherapy
25%
Quality of Life
18%
Immunotherapy
16%
Pembrolizumab
16%
Biological Marker
14%
Malignant Neoplasm
13%
Symptom
13%
Prevalence
13%
Overall Survival
13%
Progression Free Survival
13%
Monotherapy
10%
Skin Biopsy
9%
Oxaliplatin
9%
Supplementation
9%
Prematurity
9%
Tumor Microenvironment
8%
Tumor Progression
8%
Neutrophil
8%
T Cell
8%
Biopsy
8%
Neoplasm
8%
Immunocompetent Cell
8%
Effector Cell
8%
Plasmacytoid Dendritic Cell
8%
Programmed Death-Ligand 1
8%
Gene Expression
8%
down Regulation
8%
Upregulation
8%
Phase II Trials
5%
Circulating Tumor DNA
5%
Post-Hoc Analysis
5%
Electrocorticography
5%
Frailty
5%
Interleukin-6
5%
Drug Therapy
5%
Recommended Drug Dose
5%
Immunology and Microbiology
Electroporation
100%
Pembrolizumab
66%
Pancreas
50%
Immunity
50%
Immunotherapy
41%
Overall Survival
33%
Progression Free Survival
33%
Interleukin-6
25%
Recommended Drug Dose
25%
Plasmacytoid Dendritic Cell
20%
T Cell
20%
Immunocompetent Cell
20%
Preclinical Study
20%
Effector Cell
20%
Pinprick Test
16%
Cytokine
12%
Neutrophil Granulocyte
8%
Downregulation
8%
Myeloid-Derived Suppressor Cell
8%
Programmed Death-Ligand 1
8%
Gene Expression
8%
Upregulation
8%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Cancer
54%
Randomized Controlled Trial
54%
Pancreas Cancer
50%
Gemcitabine
50%
Oxaliplatin-Induced Peripheral Neuropathy
50%
Fish Oil
50%
Paclitaxel
50%
Chemotherapy
34%
Biological Marker
14%
Prevalence
13%
Symptom
13%
Malignant Neoplasm
13%
Monotherapy
10%
Prematurity
9%
Oxaliplatin
9%
Progression Free Survival
5%
Overall Survival
5%
Frailty
5%
Tolerability
5%
Pharmacotherapy
5%
Circulating Tumor DNA
5%
Phase II Trials
5%
